About Antag Therapeutics
Antag Therapeutics is a company based in Copenhagen (Denmark) founded in 2017 by Alexander Sparre-Ulrich.. Antag Therapeutics has raised $87.31 million across 4 funding rounds from investors including Pictet Group, Danmarks Eksport og Investeringsfond and Versant Ventures. The company has 2 employees as of December 31, 2022. Antag Therapeutics offers products and services including GIPR Antagonists and AT-7687.
- Headquarter Copenhagen, Denmark
- Employees 2 as on 31 Dec, 2022
- Founders Alexander Sparre-Ulrich
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Antag Therapeutics
-
Annual Revenue
-
Net Profit
$-1.39 M (USD)34as on Dec 31, 2022
-
EBITDA
$-1.7 M (USD)31as on Dec 31, 2022
-
Total Equity Funding
$87.31 M (USD)
in 4 rounds
-
Latest Funding Round
$84.06 M (USD), Series A
Dec 03, 2024
-
Investors
Pictet Group
& 6 more
-
Employee Count
2
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Antag Therapeutics
Antag Therapeutics offers a comprehensive portfolio of products and services, including GIPR Antagonists and AT-7687. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Peptide-based therapies are developed for the modulation of GIP biology to treat obesity and cardiometabolic disorders
A first-in-class GIPR antagonist is designed to induce weight loss and address gaps in obesity treatment through safety and metabolic effects
Funding Insights of Antag Therapeutics
Antag Therapeutics has successfully raised a total of $87.31M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $84.06 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $84.1M
-
First Round
First Round
(10 Oct 2018)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Series A - Antag Therapeutics | Valuation |
investors |
|
| May, 2022 | Amount | Seed - Antag Therapeutics | Valuation |
investors |
|
| Jun, 2021 | Amount | Seed - Antag Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Antag Therapeutics
Antag Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Pictet Group, Danmarks Eksport og Investeringsfond and Versant Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Antag Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Antag Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Antag Therapeutics Comparisons
Competitors of Antag Therapeutics
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Antag Therapeutics
When was Antag Therapeutics founded?
Antag Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Antag Therapeutics located?
Antag Therapeutics is headquartered in Copenhagen, Denmark.
Who is the current CEO of Antag Therapeutics?
Joerg Moeller is the current CEO of Antag Therapeutics.
Is Antag Therapeutics a funded company?
Antag Therapeutics is a funded company, having raised a total of $87.31M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1.59M, raised on Oct 10, 2018.
How many employees does Antag Therapeutics have?
As of Dec 31, 2022, the latest employee count at Antag Therapeutics is 2.
What does Antag Therapeutics do?
Antag Therapeutics was founded in 2017 in Copenhagen, Denmark, within the biotechnology sector. Peptide-based therapies are developed to address obesity and cardiometabolic disorders. Optimized analogues of naturally occurring GIP receptor inhibitors are created to facilitate weight loss and obesity treatment, while common gastrointestinal side effects are minimized. Operations focus on therapeutic innovation for these conditions, with leadership provided by Co-Founder and COO Alexander Sparre-Ulrich and CEO Joerg Moeller.
What products or services does Antag Therapeutics offer?
Antag Therapeutics offers GIPR Antagonists and AT-7687.
Who are Antag Therapeutics's investors?
Antag Therapeutics has 7 investors. Key investors include Pictet Group, Danmarks Eksport og Investeringsfond, Versant Ventures, Novo Holdings, and SR One.
What is Antag Therapeutics's valuation?
The valuation of Antag Therapeutics is $14.52M as of May 2022.